Navigation Links
Nektar Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/4/2010

linical studies. In oncology, NKTR-102, a novel topoisomerase I-inhibitor, is being evaluated in Phase 2 clinical studies for the treatment of ovarian, breast and colorectal cancers. NKTR-105, a novel anti-mitotic agent, is in a Phase 1 clinical study in cancer patients with refractory solid tumors.

Nektar's technology has enabled nine approved products in the U.S. or Europe through partnerships with leading biopharmaceutical companies, including UCB's Cimzia(R) for Crohn's disease and rheumatoid arthritis, Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for neutropenia.

Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville, Alabama and Hyderabad, India. Further information about the company and its drug development programs and capabilities may be found online at http://www.nektar.com.

This press release contains forward-looking statements that reflect management's current views regarding the value and potential of Nektar's pipeline of drug candidates, the value and potential of Nektar's technology platform, and the value and potential of certain of Nektar's collaborations with third parties.  These forward-looking statements involve numerous risks and uncertainties, including but not limited to: (i) Nektar's product candidates and those of its collaboration partners are in various stages of clinical development and the risk of failure is high and can unexpectedly occur at any stage prior to regulatory approval for numerous reasons including safety and efficacy findings even after positive findings in preclinical and clinical studies; (ii) the timing of the commencement or end of clinical trials and the successful commercial launch of our drug candidates may be delayed or unsuccessful due to slower than anticipated patient enrollment, manufacturing challenges, changing standards of care, regulatory delays and requirements, clinical trial design
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Nektar to Announce Financial Results for the Third Quarter of 2010 on Thursday, November 4, 2010, After Close of U.S.-Based Financial Markets
2. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
3. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
4. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
5. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
6. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
7. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
8. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
9. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
10. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
11. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... -- Thoratec Corporation (NASDAQ: THOR ), a world ... support and restore failing hearts, said today it will ... On Tuesday, December 2, the company will participate in ... D. Keith Grossman , President and Chief Executive ... at 11:30 a.m., Eastern Standard Time (8:30 a.m., Pacific ...
(Date:11/26/2014)... 2014  Cohen, Placitella & Roth, PC is ... purchased Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... January 31, 2011 through November 2, 2014 ("Class ... of its officers and directors publically disseminated materially ... 10(b) and 20(a) of the Securities Exchange Act ...
(Date:11/26/2014)... ALISO VIEJO, Calif. , Nov. 26, 2014 ... today announced that the U.S. Food and Drug ... to its New Drug Application (NDA) for AVP-825. ... of low-dose sumatriptan powder delivered intranasally utilizing a ... In the Complete Response letter, and consistent with ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 2Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 3Avanir Pharmaceuticals Receives Complete Response Letter (CRL) from FDA on AVP-825 NDA 4
... 5, 2011 Reportlinker.com announces that ... available in its catalogue: ... Assessments of Leading Suppliers ... This report provides industry executives with ...
... Oct. 5, 2011 Reportlinker.com announces ... is available in its catalogue: ... Dermatological Drugs, 7th Edition ... This Kalorama Information report details the ...
Cached Medicine Technology:Global CNS Drug Market: Strategic Assessments of Leading Suppliers 2Global CNS Drug Market: Strategic Assessments of Leading Suppliers 3Global CNS Drug Market: Strategic Assessments of Leading Suppliers 4Global CNS Drug Market: Strategic Assessments of Leading Suppliers 5Global CNS Drug Market: Strategic Assessments of Leading Suppliers 6Global CNS Drug Market: Strategic Assessments of Leading Suppliers 7The Market for Prescription Dermatological Drugs, 7th Edition 2The Market for Prescription Dermatological Drugs, 7th Edition 3The Market for Prescription Dermatological Drugs, 7th Edition 4The Market for Prescription Dermatological Drugs, 7th Edition 5The Market for Prescription Dermatological Drugs, 7th Edition 6The Market for Prescription Dermatological Drugs, 7th Edition 7The Market for Prescription Dermatological Drugs, 7th Edition 8The Market for Prescription Dermatological Drugs, 7th Edition 9The Market for Prescription Dermatological Drugs, 7th Edition 10The Market for Prescription Dermatological Drugs, 7th Edition 11The Market for Prescription Dermatological Drugs, 7th Edition 12The Market for Prescription Dermatological Drugs, 7th Edition 13The Market for Prescription Dermatological Drugs, 7th Edition 14The Market for Prescription Dermatological Drugs, 7th Edition 15
(Date:11/27/2014)... (PRWEB) November 28, 2014 This is ... of the global Bronchoscopes industry with a focus on ... the market status of the Bronchoscopes manufacturers and is ... and individuals interested in the industry. , Firstly, the ... its definition, applications and manufacturing technology. Then, the report ...
(Date:11/27/2014)... The American Society for Clinical Pathology (ASCP) ... in honor of World AIDS Day 2014. On Nov. 25, ... cure.” icon and infographic designed to generate public awareness about ... HIV. , ASCP has asked members to replace their Facebook, ... Get Tested. Find a cure.” icon and share the accompanying ...
(Date:11/27/2014)... 27, 2014 According to a recent ... looking to break into the surgical robotics market ... other than the MIS field dominated by Intuitive. These ... U.S. surgical robotics market by 2020. , “The ... Kamran Zamanian, CEO and President of iData. “System sales ...
(Date:11/27/2014)... November 27, 2014 In a ... allot to sleep has lessened, and due to ... the quality of sleep has eroded. According to ... on the job (Reference: http://www.webmd.com/sleep-disorders/features/sleep-deprivation-workplace ). This ... index by an incalculable amount, leading not only ...
(Date:11/27/2014)... PITTSBURGH, PA (PRWEB) November 27, 2014 ... suffer the embarrassing side effects of urinary incontinence," said ... to it and developed this specialized accessory to prevent ... developed the Incontinence to absorb urine leakage. This prevents ... wearer from potential embarrassment. The pad ensures that the ...
Breaking Medicine News(10 mins):Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 2Health News:Bronchoscopes Industry 2019 Forecasts for Global and China Region in New Research Report at ReportsnReports.com 3Health News:ASCP Launches Social Media Campaign in Honor of World AIDS Day 2Health News:U.S. Robotic Surgery Market Set to Diversify and Grow: Intuitive Surgical’s ‘da Vinci’ Robot Revenues to Increasingly Rely On Procedures and Services 2Health News:Research Shows Surprising Number of US Workers Affected by Lack of Sleep 2
... 21 Omnicell,Inc. (Nasdaq: OMCL ), a leading ... results for its first quarter ended,March 31, 2008., ... totaled $62.1,million, up $4.1 million or 7.2% from the ... from the first quarter of 2007., First quarter ...
... MDS Board, TORONTO, April 21 /PRNewswire-FirstCall/ - MDS ... and services to the global life,sciences markets, today announced ... William Dempsey, former Executive Vice-President,of Abbott Laboratories, have been ... both Greg and Bill and look forward to benefiting ...
... 6 millimeters in diameter appear more likely to be ... the April issue of Archives of Dermatology, one of ... guidelines currently used by dermatologists to screen for melanoma ... to screen for melanoma, according to background information in ...
... Insurance,Holdings, Inc. ("EIHI") (Nasdaq: EIHI ) today ... (Excellent) financial strength ratings of EIHI members,Eastern Alliance ... Company ("ELH") and upgraded the outlook for EAIG ... specializing in workers,compensation. A.M. Best reaffirmed a stable ...
... also finds survival rates similar, no matter when admission ... to heart attack patients who arrive at hospitals during ... hours tend to receive faster and more comprehensive care, ... affect in-hospital death rates of heart attack patients, said ...
... Successful Transition, BIRMINGHAM, Ala., April 21 ... Hayek has been named president and,chief executive officer ... executive officer, Mike Snow, is resigning his position ... as an advisor on the company,s,board of directors., ...
Cached Medicine News:Health News:Omnicell Announces First Quarter 2008 Results 2Health News:Omnicell Announces First Quarter 2008 Results 3Health News:Omnicell Announces First Quarter 2008 Results 4Health News:Omnicell Announces First Quarter 2008 Results 5Health News:Omnicell Announces First Quarter 2008 Results 6Health News:Omnicell Announces First Quarter 2008 Results 7Health News:Omnicell Announces First Quarter 2008 Results 8Health News:Omnicell Announces First Quarter 2008 Results 9Health News:Omnicell Announces First Quarter 2008 Results 10Health News:Omnicell Announces First Quarter 2008 Results 11Health News:MDS Appoints Two New Directors 2Health News:MDS Appoints Two New Directors 3Health News:Larger skin lesions appear more likely to be melanomas 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 2Health News:Eastern Alliance Insurance Group and Eastern Life and Health Insurance Company Announce Affirmation of A- (Excellent) A.M. Best Ratings and a Positive Outlook for Eastern Alliance Insurance Group 3Health News:Off-Hours Heart Patients Less Likely to Get Angioplasty 2Health News:SCA Names Andrew Hayek as New President and CEO 2
The Accucount 2000 is designed to automatically count microscopic objects in a field displaying totals on a highly visible digital readout....
... is a Accelerated Bacterial Enumeration System. Bacterial ... of colonies found by the volume dispensed ... A logarithmically decreasing volume of sample is ... Petri dish in an Archimedes spiral. The ...
... The CA-1000 rapidly analyses the Petri dishes ... ensures reliable and reproducible results. A CCD ... the image to a dedicated computer. The ... into account and compensate for spreading and ...
... Gas Monitoring System provides a ... measurements of pH, pCO2, pO2 ... artery (e.g. radial, femoral or ... of O2 saturation; base-excess and ...
Medicine Products: